Vendor, Seattle, WA
Access to Advanced Health Institute
UEI EMQ1ANLATYS6, CAGE 06UF1
3 awards and -$11,646 obligated between March 5, 2025 and August 31, 2026, 100% under full and open competition, against 18.3 offers on average where reported.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 3 |
| Definitive Contract | 3 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93018C00025Definitive Contract, March 6, 2025, Full and Open Competition, 24 offers | National Institutes of Health NiaidNational Institutes of Health | The Purpose of This Contract Is to Enable Advanced Preclinical Development of an Intranasal Recombinant Amebiasis Vaccine Containing a LiposNAICS 541714, PSC AN12 | $0 |
| 75N93023C00018Definitive Contract, March 5, 2025, Full and Open Competition, 19 offers | National Institutes of Health NiaidNational Institutes of Health | BAA Research Area 001: Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (Amr) Infections and Emerging Infectious DiNAICS 541715, PSC AN12 | $0 |
| 75N93019C00059Definitive Contract, April 25, 2025, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | Eoi::implementing the Presidents Department of Government Efficiency Cost Efficiency Initiative (March 19, 2025)::EOI Terminate for ConvenieNAICS 541714, PSC AN12 | -$11,646 |
- Places of performance
- Washington
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 11 across 3 awards